Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation

Endocrinology

Volumn 153, Issue 12, 2012, Pages 5716-5725

  Gong, Yanqing ^a,b   Wang, Dan ^c   Dar, Javid A ^c   Singh, Prabhpreet ^c   Graham, Lara ^c   Liu, Weijun ^c   Ai, Junkui ^c   Xin, Zhongcheng ^a,b   Guo, Yinglu ^a,b,c   Wang, Zhou ^c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NATIONAL UROLOGICAL CANCER CENTER   (China)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PROTEASOME;

AGGRESOME; ARTICLE; CANCER CELL; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MALE; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN STABILITY; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; LEUPEPTINS; LIGANDS; MALE; POLYUBIQUITIN; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TIME FACTORS; UBIQUITIN;

EID: 84870209819     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1841     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E 2010 Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Shen MM, Abate-Shen C 2010 Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24:1967-2000
3. Kozlowski J, Grayhack J 1991 Carcinoma of the prostate. 2nd ed. Chicago: Mosby Year Book
4. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A 2011 EAU guidelines on prostate cancer. II. Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572-583
5. Courtney KD, Taplin ME 2012 The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Curr Opin Oncol 24:272-277
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
7. Sharma P, Wagner K, Wolchok JD, Allison JP 2011 Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805-812
8. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790
9. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF 2011 New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 60:279-290
10. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ 2002 Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013
11. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
12. Zhou ZX, Wong C, Sar M, Wilson EM 1994 The androgen receptor: an overview. [Review]. Recent Prog Horm Res 49:249-274
13. Lonergan PE, Tindall DJ 2011 Androgen receptor signaling in prostate cancer development and progression. J Carcinog 10:20
14. Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC, Sultan C 1997 Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 129:17-26
15. Roy AK, Tyagi RK, Song CS, Lavrovsky Y, Ahn SC, Oh TS, Chatterjee B 2001 Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann NY Acad Sci 949:44-57
16. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK 2000 Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 14:1162-1174
17. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM 1994 A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem 269:13115-13123
18. Picard D, Yamamoto KR 1987 Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J 6:3333-3340
19. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z 2003 Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 278:41998-42005
20. Poukka H, Karvonen U, Yoshikawa N, Tanaka H, Palvimo JJ, Jänne OA 2000 The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci 113:2991-3001
21. Gregory CW, Johnson Jr RT, Mohler JL, French FS, Wilson EM 2001 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898
22. Nguyen MM, Dincer Z, Wade JR, Alur M, Michalak M, Defranco DB, Wang Z 2009 Cytoplasmic localization of the androgen receptor is independent of calreticulin. Mol Cell Endocrinol 302:65-72
23. Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lähdesmäki H, Jänne OA, Visakorpi T 2012 Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31:2153-2163
24. Urbanucci A, Marttila S, Jänne OA, Visakorpi T 2012 Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure. Prostate 72:1223-1232
25. Petroski MD 2008 The ubiquitin system, disease, and drug discovery. BMC Biochem 9(Suppl 1):S7
26. Voutsadakis IA, Papandreou CN 24 June 2010 The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance. Urol Oncol 10.1016/j.urolonc.2010.03.013
27. Kang Z, Pirskanen A, Jänne OA, Palvimo JJ 2002 Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277:48366-48371
28. Godfrey B, Lin Y, Larson J, Haferkamp B, Xiang J 2010 Proteasomal degradation unleashes the pro-death activity of androgen receptor. Cell Res 20:1138-1147
29. Sheflin L, Keegan B, Zhang W, Spaulding SW 2000 Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276:144-150
30. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C 2002 Phosphorylation- dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21:4037-4048
31. Jaworski T 2006 Degradation and beyond: control of androgen receptor activity by the proteasome system. Cell Mol Biol Lett 11:109-131
32. Sakamoto KM, Kim KB, Verma R, Ransick A, Stein B, Crews CM, Deshaies RJ 2003 Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics 2:1350-1358
33. Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim K, Crews CM, Deshaies RJ, Sakamoto KM 2008 Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27:7201-7211
34. Zaarur N, Meriin AB, Gabai VL, Sherman MY 2008 Triggering aggresome formation. Dissecting aggresome-targeting and aggregation signals in synphilin 1. J Biol Chem 283:27575-27584
35. Olzmann JA, Li L, Chin LS 2008 Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem 15:47-60
36. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM 2004 Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279:4625-4631
37. Hicke L, Schubert HL, Hill CP 2005 Ubiquitin-binding domains. Nat Rev Mol Cell Biol 6:610-621
38. Johnston JA, Ward CL, Kopito RR 1998 Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143:1883-1898
39. Bandopadhyay R, Kingsbury AE, Muqit MM, Harvey K, Reid AR, Kilford L, Engelender S, Schlossmacher MG, Wood NW, Latchman DS, Harvey RJ, Lees AJ 2005 Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiol Dis 20:401-411
40. Kovacs I, Lentini KM, Ingano LM, Kovacs DM 2006 Presenilin 1 forms aggresomal deposits in response to heat shock. J Mol Neurosci 29:9-19
41. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP 2003 The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727-738
42. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner Jr K, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ 2006 Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66:3773-3781
43. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ 2010 Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 70:9265-9276
44. Shiota M, Yokomizo A, Naito S 2011 Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 47:R25-R41
45. Lee DK, Chang C 2003 Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 88:4043-4054
46. Kemppainen JA, Lane MV, Sar M, Wilson EM 1992 Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267:968-974
47. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM 1995 Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208-218